CalciMedica financials
$1.61−4.17%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — |
| Operating income | -$23.1M | -$24.2M | -$38.1M |
| Net income | -$29.6M | -$13.7M | -$34.4M |
| Net margin | — | — | — |
| Diluted EPS | $-9.85 | $-6.10 | $-38.30 |
| EBITDA | -$23.1M | -$24.1M | -$38.0M |
| Operating cash flow | -$21.2M | -$21.1M | -$25.7M |
| Free cash flow | -$21.2M | -$21.2M | -$25.8M |
| Diluted shares | 3.0M | 2.2M | 0.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $11.5M | $7.9M | $5.5M |
| Short-term investments | $1.5M | $10.7M | $5.7M |
| Total debt | $9.7M | $0.00 | $0.00 |
| Total assets | $13.6M | $19.8M | $12.2M |
| Total liabilities | $20.2M | $5.4M | $4.0M |
| Shareholders' equity | -$6.6M | $14.4M | $8.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology